aTyr Pharma Shares Plunge 83.2% Following EFZO-FIT Study Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 04 2025
0mins
Source: PRnewswire
- Stock Price Plunge: aTyr Pharma's stock plummeted 83.2% from $6.03 to $1.02 on September 15, 2025, following the announcement that the EFZO-FIT study did not meet its primary endpoint, indicating extreme market pessimism regarding the company's future prospects.
- Investor Confidence Eroded: Prior to the study results, aTyr conveyed overly optimistic messages to investors, leading to misconceptions about the efficacy of its drug Efzofitimod, which adversely affected the company's reputation and market trust.
- Next Steps Announced: The company stated it would engage with the FDA to determine a path forward, demonstrating a proactive approach to restoring market confidence in the wake of disappointing results.
- Class Action Notice: The Gross Law Firm is offering a class action opportunity for shareholders who purchased aTyr stock between November 7, 2024, and September 12, 2025, highlighting the importance of investor protection and available legal recourse.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on ATYR
Wall Street analysts forecast ATYR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATYR is 7.33 USD with a low forecast of 1.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
1 Buy
3 Hold
0 Sell
Hold
Current: 0.674
Low
1.00
Averages
7.33
High
20.00
Current: 0.674
Low
1.00
Averages
7.33
High
20.00
About ATYR
aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase-derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and potentially prevent the progression of fibrosis. ATYR0101 is a fusion protein derived from a domain of aspartyl-tRNA synthetase (DARS). ATYR0750 is a fusion protein derived from the domain of alanyl-tRNA synthetase (AARS). ATYR0750 is a novel ligand to fibroblast growth factor receptor 4 (FGFR4).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
aTyr Pharma Faces Shareholder Lawsuit Investigation Over Phase 3 Trial Disclosures
- Lawsuit Investigation Launched: Johnson Fistel, PLLP is investigating potential derivative claims on behalf of aTyr Pharma, Inc. concerning fiduciary breaches related to disclosures from November 7, 2024, to September 12, 2025, which could impact the company's reputation and shareholder interests.
- Clinical Trial Results Impact: Following negative results from the Phase 3 EFZO-FIT clinical trial, aTyr's stock price dropped significantly, indicating management failures in clinical disclosure controls that may expose the company to litigation risks.
- Shareholder Rights Protection: Shareholders who have continuously held aTyr shares during the investigation period may have standing to pursue derivative claims on behalf of the company, aiming to protect their investment interests and seek compensation.
- Legal Firm Background: Johnson Fistel, PLLP is a nationally recognized shareholder rights law firm specializing in securities fraud and investor rights, providing legal support to help investors recover losses, highlighting its expertise in safeguarding shareholder interests.
Continue Reading
aTyr Pharma Faces Shareholder Derivative Claims Investigation Over Phase 3 Trial Disclosures
- Investigation Launched: Johnson Fistel, PLLP is investigating potential derivative claims on behalf of aTyr Pharma, Inc. concerning fiduciary breaches related to disclosures from November 7, 2024, to September 12, 2025, which may expose shareholders to significant losses.
- Clinical Trial Controversy: Allegations suggest that aTyr made false or misleading statements regarding the design and expectations of the Phase 3 EFZO-FIT trial, leading to a substantial drop in stock price following negative trial results, indicating management failures in clinical disclosure oversight.
- Shareholder Rights Protection: Current shareholders who held aTyr shares continuously before November 7, 2024, may have standing to pursue derivative claims, aiming to protect shareholder interests and seek potential compensation for losses incurred.
- Reputational Risk Heightened: The board's failure to oversee disclosures adequately could lead to broader legal repercussions, undermining investor confidence and negatively impacting the company's future financing capabilities.
Continue Reading